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Introduction {#sec1}
============

Tissue engineering technology has become one of the most prospective therapeutic approaches for bone regeneration in bone defects ([@bib14], [@bib37]). As a type of adult mesenchymal stem cells (MSCs), human adipose-derived mesenchymal stem cells (hASCs) are capable of self-renewal and differentiation into cells such as osteoblasts, chondrocytes, and adipocytes ([@bib56]). Because they can be obtained from adipose tissue in abundance by means of a minimally invasive procedure, hASCs are a valuable source of adult MSCs for bone tissue engineering and bone regeneration ([@bib3]). Therefore, how to effectively promote the osteogenic differentiation of hASCs has become dramatically important in bone tissue engineering.

MicroRNAs (miRNAs) are a class of endogenously small non-coding RNAs that function as post-transcriptional regulators through binding to complementary sites on target mRNAs ([@bib15]). Evolutionary conserved, miRNAs have been implicated in various biological processes, including the cell fate of embryonic stem cells, cell proliferation, apoptosis, differentiation, and carcinogenesis ([@bib12], [@bib13], [@bib18]). A number of miRNAs participate in the osteogenic differentiation of MSCs, such as miR-21 ([@bib45]), miR-31 ([@bib6]), miR-34a ([@bib11]), and miR-196a ([@bib23]). Targeting miRNAs as a therapeutic approach has shed light on bone tissue regeneration, but the mechanism of their regulation of osteogenesis in MSCs remains to be determined ([@bib53]).

microRNA-375 (miR-375) was identified early as a pancreatic islet-specific miRNA regulating insulin secretion ([@bib38]). Subsequent studies revealed that miR-375 participated in multiple biological processes, including glucose homeostasis, mucosal immunity, and cancer development ([@bib2], [@bib10], [@bib50]). Moreover, miR-375 is significantly downregulated in several types of tumors, and suppresses their proliferation by targeting some important genes, e.g., *JAK2*, *YAP1*, and *PDK1* ([@bib8], [@bib52], [@bib55]). Research has shown that miR-375 is a negative regulator of adipogenic differentiation by targeting bone morphogenetic protein receptor 2 (BMPR2) ([@bib29]). Osteoblastic and adipocytic lineages have alternative fates during development and aging, and increased adipogenesis correlates with decreased osteogenesis ([@bib46], [@bib48]), which led us to speculate that miR-375 might play a role in the differentiation of stem cells toward osteogenic lineage.

Osteogenic differentiation is a complex process governed by interplay of several signaling pathways ([@bib35], [@bib39]). Phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) and Hippo are two major pathways involved in the regulation of cell proliferation and differentiation ([@bib16], [@bib25]). Crosstalk between the two pathways plays a significant role in regulating cell proliferation and differentiation ([@bib17], [@bib43]). The PI3K/AKT/mTOR pathway governs a variety of cellular and molecular responses by regulating protein synthesis ([@bib7]). Perturbation of this pathway contributes to the maintenance of bone homeostasis and MSC lineage differentiation ([@bib32]). The Hippo pathway plays a crucial role in organ-size control by modulating cell proliferation and apoptosis ([@bib54]). Yes-associated protein 1 (YAP1), major downstream effector of the Hippo pathway, inhibits the osteogenic differentiation of bone marrow-derived MSCs (BMSCs) ([@bib41], [@bib42]). In this study, we evaluated the effects of miR-375 in hASC osteogenesis and demonstrated that miR-375 promoted the osteogenic differentiation of hASCs via a YAP1/DEPTOR/AKT regulatory network, suggesting its potential utility in hASC-based bone tissue engineering.

Results {#sec2}
=======

miR-375 Is Upregulated during the Osteogenic Differentiation of hASCs {#sec2.1}
---------------------------------------------------------------------

The expression of miR-375 was determined by qRT-PCR at various time points during hASC osteogenesis. The result showed that miR-375 expression was upregulated after induction to the osteogenic lineage and remained at a high level during osteogenesis ([Figure 1](#fig1){ref-type="fig"}A). Moreover, the expression levels of osteogenic markers *RUNX2*, alkaline phosphatase (*ALP*), and osteocalcin (*OCN*) were also upregulated during the osteogenic differentiation ([Figures 1](#fig1){ref-type="fig"}B--1D).

miR-375 Promotes the Osteogenic Differentiation of hASCs In Vitro {#sec2.2}
-----------------------------------------------------------------

Lentivirus was used to overexpress or knock down miR-375 in hASCs. The transduction efficiency was estimated to be more than 80%, as evaluated by the percentage of GFP-positive cells 72 hr after transduction ([Figure S1](#mmc1){ref-type="supplementary-material"}A). qRT-PCR analysis of miR-375 expression confirmed an almost 100-fold increase in the miR-375 overexpression group (miR-375) and a ∼70% decrease in the miR-375 knockdown group (anti-miR-375) compared with the control group (negative control \[NC\] or anti-NC) ([Figure S1](#mmc1){ref-type="supplementary-material"}B). ALP staining and quantification showed that overexpression of miR-375 enhanced the osteogenic differentiation of hASCs cultured in proliferation medium (PM) or osteogenic medium (OM) on day 7 ([Figures 2](#fig2){ref-type="fig"}A and 2B), while miR-375 knockdown inhibited the ALP activity ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B). The extracellular mineralization of hASCs, as measured by alizarin red S (ARS) and von Kossa (VK) staining in PM or OM on days 14 and 21, respectively, displayed outcomes similar to those of ALP assays ([Figures 2](#fig2){ref-type="fig"}A, 2B, [S2](#mmc1){ref-type="supplementary-material"}A, and S2B). Consistently, overexpression of miR-375 significantly increased the expression of osteogenesis-associated genes, including *RUNX2*, *ALP*, osterix (*OSX*), and *OCN* ([Figure 2](#fig2){ref-type="fig"}C), while miR-375 knockdown showed the opposite tendency ([Figure S2](#mmc1){ref-type="supplementary-material"}C). Moreover, immunofluorescence staining and western blotting indicated that the protein level of OCN was increased in the miR-375 overexpression group ([Figures 2](#fig2){ref-type="fig"}D and 2E) and reduced in the miR-375 knockdown group ([Figures S2](#mmc1){ref-type="supplementary-material"}D and S2E).

miR-375 Promotes the Osteogenic Differentiation of hASCs In Vivo {#sec2.3}
----------------------------------------------------------------

hASCs expressing miR-375 and NC were loaded onto scaffolds and implanted in the subcutaneous space of nude mice (six mice per group) ([Figure 3](#fig3){ref-type="fig"}A). After 8 weeks, the implantation samples were harvested and subjected to computed microtomography (micro-CT) imaging. Representative images showed that the miR-375 overexpression group exhibited more newly formed bone with fewer scaffold remnants compared with the NC group ([Figure S3](#mmc1){ref-type="supplementary-material"}A). Moreover, the percentages of bone volume to tissue volume (BV/TV) ratio in the miR-375 overexpression group was almost three times higher than that in the NC group, and the percentage of bone surface to tissue volume (BS/TV) ratio in the miR-375 overexpression group was lower than that in the NC group ([Figure S3](#mmc1){ref-type="supplementary-material"}B). H&E staining revealed little newly formed bone in the NC group, while osteoid was formed in the miR-375 overexpression group. Collagen organization with blue color in Masson\'s trichrome staining was significantly higher in the miR-375 overexpression group. Furthermore, immunohistochemical staining for OCN indicated that both the range and intensity of the stained granules in osteoblasts were generally increased in the miR-375 overexpression group ([Figure 3](#fig3){ref-type="fig"}B).

miR-375 Inhibits *DEPTOR* by Targeting Its 3′ UTR {#sec2.4}
-------------------------------------------------

To evaluate the molecular mechanisms by which miR-375 regulates osteogenic differentiation, we established miR-375-overexpressing hASCs and conducted a transcriptome microarray analysis 7 days after osteoinduction. A scatterplot showed overexpression of miR-375 resulting in upregulation of 106 genes and downregulation of 91 ([Figure 4](#fig4){ref-type="fig"}A). Pathway analysis reveals that miR-375 is involved in the organization of extracellular matrix, and several signaling pathways, such as nuclear factor κB, PI3K-AKT, and mitogen-activated protein, are enriched in this process ([Figure 4](#fig4){ref-type="fig"}B). Among the downregulated genes, *DEPTOR* was distinguished by a particularly marked decrease ([Table S1](#mmc1){ref-type="supplementary-material"}). qRT-PCR and western blot analysis confirmed that DEPTOR expression was decreased in miR-375-overexpressing hASCs compared with control cells ([Figures 4](#fig4){ref-type="fig"}C and 4D). We next assessed the putative binding site of miR-375 in the 3′ UTR of *DEPTOR* using RNA22 prediction software ([Figure 4](#fig4){ref-type="fig"}E). Luciferase activity analysis showed that miR-375 repressed the luciferase expression of vectors containing the 3′ UTR of wild-type *DEPTOR* (*DEP*-WT), but had no effect on the mutant-type *DEPTOR* (*DEP*-MT) ([Figure 4](#fig4){ref-type="fig"}F).

Knockdown of *DEPTOR* Promotes the Osteogenic Differentiation of hASCs {#sec2.5}
----------------------------------------------------------------------

To investigate the role of *DEPTOR* in hASCs osteogenesis, we determined its expression by qRT-PCR at various time points after induction to the osteogenic lineage. The result showed that *DEPTOR* expression was dramatically downregulated and remained at a low level during the osteogenic differentiation of hASCs ([Figure 5](#fig5){ref-type="fig"}A), which is a tendency opposite to that of miR-375 expression ([Figure 5](#fig5){ref-type="fig"}B). Two *DEPTOR* small interfering RNA (siRNA) sequences were designed to knock down *DEPTOR* in hASCs, and the knockdown efficiency was ∼30% as determined by qRT-PCR and western blot ([Figures 5](#fig5){ref-type="fig"}C and 5D). Moreover, ALP staining and quantification showed that knockdown of *DEPTOR* accelerated the osteogenic differentiation of hASCs cultured in PM or OM on day 7 ([Figures 5](#fig5){ref-type="fig"}E and 5F). The extracellular matrix mineralization, as measured by ARS staining and quantification on day 14, was also increased in *DEPTOR* siRNA-treated cells ([Figures 5](#fig5){ref-type="fig"}E and 5F). Moreover, expression of RUNX2 and OCN at both mRNA and protein levels was significantly elevated in *DEPTOR* knockdown groups ([Figures 5](#fig5){ref-type="fig"}G and 5H).

miR-375 Inhibits AKT Signaling by Directly Targeting *DEPTOR* {#sec2.6}
-------------------------------------------------------------

Since DEPTOR has been reported as an endogenous mTOR inhibitor ([@bib36]), we further examined mTOR complex 1 (mTORC1) and mTORC2 pathway status in *DEPTOR* knockdown hASCs. The phosphorylated form of S6K (Thr389), a downstream effector of mTORC1, increased in *DEPTOR* knockdown groups ([Figures 6](#fig6){ref-type="fig"}A and 6B), indicating activation of mTORC1. In contrast, the level of phospho-mTOR at Ser2448 was downregulated in *DEPTOR* knockdown groups ([Figures 6](#fig6){ref-type="fig"}A and 6B). Knockdown of *DEPTOR* led to suppression of the phosphorylated form of AKT (Ser473), indicating suppression of mTORC2 ([Figures 6](#fig6){ref-type="fig"}A and 6B). Moreover, knockdown of *DEPTOR* resulted in downregulation of the phospho-IRS1 (Ser636/639) level ([Figures 6](#fig6){ref-type="fig"}A and 6B). This regulation suggested a strong feedback inhibition of the IRS1-PI3K-AKT pathway by S6K. IRS1 contains several PI3K binding domains, which are responsible for the activation of PI3K and AKT. S6K phosphorylates IRS1 to prevent its binding to PI3K ([@bib25], [@bib44]). To ascertain whether miR-375 inhibited AKT signaling by directly targeting *DEPTOR*, we detected AKT signaling status in miR-375 overexpression hASCs. The results showed that overexpression of miR-375 had similar effects to those of *DEPTOR* knockdown in terms of AKT signaling ([Figures 6](#fig6){ref-type="fig"}C and 6D).

Direct Targeting of *YAP1* by miR-375 {#sec2.7}
-------------------------------------

As a transcriptional regulator, *YAP1* transcript contains a conserved miR-375 targeting site in its 3′ UTR ([@bib28], [@bib52]). Thus, we constructed luciferase reporter plasmids containing the wild-type or mutant-type miR-375 target site in the *YAP1* 3′ UTR sequence ([Figure S4](#mmc1){ref-type="supplementary-material"}A). miR-375 repressed the luciferase expression of vectors containing the 3′ UTR of wild-type *YAP1* (*YAP1*-WT), but had no effect on the mutant-type *YAP1* (*YAP1*-MT) ([Figure S4](#mmc1){ref-type="supplementary-material"}B). Overexpression of miR-375 led to downregulation of YAP1 at both mRNA and protein levels ([Figure S4](#mmc1){ref-type="supplementary-material"}C), indicating that miR-375 negatively regulates *YAP1* by binding directly to the 3′ UTR of its mRNA. Furthermore, we examined *YAP1* expression during the osteogenic differentiation of hASCs, and qRT-PCR showed that the expression of *YAP1* was decreased during osteogenic differentiation ([Figure S4](#mmc1){ref-type="supplementary-material"}D).

miR-375 and YAP1 Form a Negative Feedback Loop {#sec2.8}
----------------------------------------------

As a transcriptional factor, YAP1 plays a crucial role in the biogenesis of miRNAs ([@bib34]), we determined whether YAP1 regulates the transcription of miR-375. Two *YAP1* siRNA sequences were designed to knock down *YAP1* in hASCs, and both markedly decreased YAP1 expression ([Figure 7](#fig7){ref-type="fig"}A). qRT-PCR indicated that miR-375 expression was upregulated in *YAP1* knockdown groups ([Figure 7](#fig7){ref-type="fig"}B). We next investigated whether YAP1 is directly responsible for miR-375 transcription. A sequence analysis of the promoter region of miR-375 −4,000 bp upstream of the transcription start site revealed putative binding sites for TEAD, a transcription factor that mediates the function of YAP1 ([@bib54]). A chromatin immunoprecipitation (ChIP) assay was performed using an antibody against YAP1 and five pairs of primers flanking the region of the predicted YAP1 binding sites on the miR-375 promoter ([Figure 7](#fig7){ref-type="fig"}C). The result showed that knockdown of *YAP1* dramatically decreased the levels of *YAP1* in the fragment containing Ch-3 and Ch-4 ([Figure 7](#fig7){ref-type="fig"}D), suggesting that the distal −3,000 bp to −1,000 bp region contains a TEAD-response element. Moreover, we transfected a luciferase reporter containing the wild-type or mutant miR-375 promoter in *YAP1* knockdown cells ([Figure 7](#fig7){ref-type="fig"}E), and knockdown of *YAP1* dramatically increased the luciferase expression in cells transfected with the wild-type miR-375 promoter but not with the mutant reporter ([Figure 7](#fig7){ref-type="fig"}F).

Knockdown of *YAP1* Enhanced the Osteogenic Differentiation of hASCs {#sec2.9}
--------------------------------------------------------------------

ALP staining and quantification indicated that knockdown of *YAP1* promoted the osteogenic differentiation of hASCs cultured in PM or OM on day 7 ([Figures S5](#mmc1){ref-type="supplementary-material"}A and S5B). The extracellular matrix mineralization, as measured by ARS staining and quantification on day 14, was also increased in *YAP1* siRNA-treated cells ([Figures S5](#mmc1){ref-type="supplementary-material"}A and S5B). Moreover, expression levels of the osteogenesis-related genes *RUNX2* and *OCN* were elevated in *YAP1* knockdown groups ([Figure S5](#mmc1){ref-type="supplementary-material"}C).

Discussion {#sec3}
==========

miR-375 has been implicated in various biological processes, but its role and function in osteogenic differentiation require further investigation. In this study, we found that miR-375 was unregulated during the osteogenic differentiation of hASCs, and overexpression of miR-375 promoted hASCs osteogenesis both in vitro and in vivo. This is inconsistent with a previous report, which indicated that miR-375 exerted a negative regulatory effect on the osteogenic differentiation of C2C12 cells ([@bib9]). This difference might be attributed to cell lines utilized in the two studies. C2C12 cells were isolated from mouse myoblasts and did not have multiple differentiation potential, while hASCs used in this study were derived from human adipose tissue and capable of multi-lineage differentiation ([@bib56]). Moreover, to elucidate whether miR-375 promotes osteogenesis of MSCs from other sources, we overexpressed miR-375 in BMSCs, the results of which showed that overexpression of miR-375 also promoted the osteogenic differentiation of BMSCs (our unpublished data).

To unveil the underlying molecular mechanisms by which miR-375 promotes hASC osteogenesis, we conducted a microarray analysis 7 days after osteoinduction. According to the microarray profiles, the osteogenesis-associated genes *RUNX2* (ratio = 1.6431) and *ALP* (ratio = 1.6367) were upregulated, and *DEPTOR* expression was decreased. As an mTOR-interacting protein, DEPTOR endogenously inhibits the activity of mTOR ([@bib36]). Furthermore, DEPTOR plays a key role in maintaining the pluripotency of embryonic stem cells (ESCs) ([@bib1]). Recent studies demonstrated that DEPTOR was a crucial regulator of adipogenic differentiation, and that its overexpression and suppression promote and block adipogenesis, respectively ([@bib4], [@bib26]). Here, we showed that *DEPTOR* is downregulated during the osteogenic differentiation of hASCs and that its knockdown resulted in enhanced mineralization activity of hASCs and elevated expression of osteogenesis-associated markers. Promotion effects of miR-375 on the osteogenic differentiation of hASCs might be attributed to repression of *DEPTOR*, which leads to loss of stem cell pluripotency.

The Hippo pathway is now being recognized as an integrator of mechanical and cellular-contact-dependent sensory signals with the intracellular components that regulate cell fate ([@bib51]). Active Hippo signaling inhibits the transcriptional activity of YAP1 and TAZ by phosphorylating and sequestering them in the cytoplasm ([@bib33]). Although YAP1 and TAZ are often considered functionally analogous orthologs of *Drosophila* Yorkie (Yki), their functions in osteogenic differentiation remains distinct. TAZ was identified as a fate-determination factor that binds to and activates RUNX2, a transcriptional regulator of the osteoblast lineage, while YAP1 was downregulated during the osteogenic differentiation of MSCs and suppressed their osteogenesis by binding to β-catenin to inhibit WNT signaling ([@bib20], [@bib42]). Several studies have shown that *YAP1* contains an miR-375 target site in its 3′ UTR and represses tumorigenesis in carcinomas ([@bib28], [@bib40]). In our study, miR-375 directly targeted the predicted binding site of *YAP1*, resulting in its downregulation during the osteogenic differentiation of hASCs.

YAP1 maintains the pluripotency of ESCs by binding to a number of "stemness" genes, including Nanog, OCT4, and SOX2 ([@bib27]), and often acts as a transcriptional co-activator ([@bib19]). In some instances, YAP1 also functions as a transcriptional co-repressor ([@bib24]). Moreover, studies focused on miRNA biogenesis reveal that activation of YAP1 is responsible for the widespread miRNA repression. The mechanism might lie in DEAD box helicase 17 (DDX17), a microprocessor component. Knockdown of *YAP1* facilitates DDX17 association with microprocessor and binding to a specific sequence motif in pri-miRNA ([@bib34]). However, YAP1 conversely induces the biogenesis of some miRNAs, such as miR-16, -21, and -23, by increasing Dicer through the Let-7 family ([@bib5]). In our study, we show that knockdown of *YAP1* in hASCs increased miR-375 expression by binding to its promoter. The upregulation of miR-375 during the osteogenic differentiation of hASCs was modulated, at least in part, by the decrease in YAP1 expression.

As a nutrient sensor, mTOR responds to PI3K-mediated growth factor signaling to regulate cell growth in mammals ([@bib7]). The PI3K/AKT/mTOR pathway is involved in osteogenic differentiation and osteoporosis ([@bib31], [@bib49]). Here, we demonstrated that miR-375 overexpression activated S6K via mTORC1, leading to a negative feedback inhibition of IRS1-PI3K-AKT in hASCs, resulting in a decrease in the phosphorylated AKT level. Moreover, YAP1 inhibits the transcription of PTEN and then activates PI3K/AKT/mTOR signaling by inducing miR-29 ([@bib47]). As a key downstream effector of the Hippo pathway, YAP1 plays a crucial role in regulating cell proliferation and organ size ([@bib16]). Our research indicated that knockdown of *YAP1* induced the transcription of miR-375, thus activating AKT signaling by directly targeting *DEPTOR*. The link from YAP1 to miR-375 to DEPTOR and AKT suggests their collaboration in cell growth control, and illustrates that signaling networks function in a coordinated manner to fine-tune the osteogenic differentiation of MSCs.

In summary, our findings indicated that miR-375 promoted the osteogenic differentiation of hASCs both in vitro and in vivo, and miR-375 targeted *DEPTOR* to inhibit the activity of AKT signaling during this process. Furthermore, YAP1 together with miR-375 established a negative feedback loop to regulate osteogenesis. These findings suggest that miR-375 can be targeted to enhance bone formation and the feasibility of miRNA-targeted therapeutic approaches in bone tissue engineering.

Experimental Procedures {#sec4}
=======================

Cell Culture and Osteogenic Induction {#sec4.1}
-------------------------------------

Primary hASCs from three different healthy human donors were obtained from ScienCell. Cells between three and five passages were used for the in vitro and in vivo experiments, and all the in vitro experiments were repeated in triplicate using hASCs from three donors, respectively. hASCs were cultured in PM containing DMEM with 10% (v/v) fetal bovine serum (FBS) and 1% (v/v) antibiotics at 37°C in an incubator with an atmosphere consisting of 95% air and 5% CO~2~, with 100% relative humidity. For osteogenic differentiation, cells were cultured in OM, which consisted of DMEM with 10% (v/v) FBS, 1% (v/v) antibiotics, 100 nM dexamethasone, 10 mM β-glycerophosphate, and 0.2 mM L-ascorbic acid. 293T was obtained from the American Type Culture Collection and cultured in DMEM supplemented with 10% (v/v) FBS and 1% (v/v) antibiotics.

Lentivirus Infection {#sec4.2}
--------------------

Lentivirus infection was performed as described previously ([@bib11]). All recombinant lentiviruses were obtained from GenePharma and used for hASC infection at an MOI of 100. The packaged lentiviruses used contained pre-miR-375 (miR-375), NC, anti-sense miR-375 (anti-miR-375), and anti-sense NC (anti-NC). Infection was performed by exposing hASCs to dilutions of the viral supernatant in the presence of polybrene (5 μg/mL) and fresh medium for 24 hr, followed by selection with puromycin (Sigma-Aldrich) at 1 μg/mL. Transduction efficiency was evaluated by determining the percentage of GFP-positive cells observed under an inverted fluorescence microscope (TE2000-U, Nikon).

RNA Interference and Transient Infection {#sec4.3}
----------------------------------------

Small interfering RNAs (siRNAs) targeting *DEPTOR*, *YAP1*, and NC were purchased from GenePharma. The sequences are listed in [Table S2](#mmc1){ref-type="supplementary-material"}. For transient infection, cells were cultured and grown to 70%--90% confluence, then transfected with siRNAs using Lipofectamine 2000 (Invitrogen) according to the manufacturer\'s procedure. After 48 hr, cells were harvested for RNA and protein analyses. For osteogenic differentiation, cells were cultured in OM and harvested after 7 and 14 days.

Alkaline Phosphatase Staining and Quantification {#sec4.4}
------------------------------------------------

Cells cultured in PM or OM for 7 days were assayed for ALP staining and activity. ALP staining was performed using an NBT/BCIP staining kit (CoWin Biotech) with nitroblue tetrazolium (NBT) and 5-bromo-4-chloro-3-indolyl phosphate (BCIP). ALP quantification was measured using an ALP assay kit (Nanjing Jiancheng Bioengineering Institute). The total protein content was determined in the same sample by the BCA method using a Pierce Protein Assay Kit (Thermo Fisher Scientific). ALP activity relative to the control treatment was calculated after normalization to the total protein content.

Alizarin Red S Staining and Quantification {#sec4.5}
------------------------------------------

Cells cultured in PM or OM for 14 days were assayed for ARS staining and quantification. Cultured cells were fixed in 4% paraformaldehyde and then stained with 1% ARS (pH 4.2; Sigma-Aldrich) for 20 min at room temperature. For quantitative assessment of the degree of mineralization, the stain was dissolved with 100 mM cetylpyridinium chloride (Sigma-Aldrich) for 1 hr and quantified by spectrophotometric absorbance at 570 nm. ARS intensity relative to the control treatment was calculated after normalization to the total protein content.

Von Kossa Staining {#sec4.6}
------------------

Cells cultured in PM or OM for 21 days were assayed using the VK staining method as described previously ([@bib22]). In brief, cells were fixed with 4% paraformaldehyde for 30 min at room temperature and then incubated with 5% silver nitrate solution for 1 hr by exposure to a 50-W UV lamp. Unincorporated silver nitrate was removed using 5% sodium thiosulfate and rinsed three times with distilled water.

RNA Extraction, Reverse Transcription, and Real-Time qPCR {#sec4.7}
---------------------------------------------------------

Total cellular RNAs were isolated on 7 and 14 days after osteoinduction using TRIzol reagent (Invitrogen) and used for first-strand cDNA synthesis with a Reverse Transcription System (Takara Bio). Quantification of all gene transcripts was performed by real-time qPCR using a Power SYBR Green PCR Master Mix (Roche) and a 7500 Real-Time PCR Detection System (Applied Biosystems). The following thermal settings were used: 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. The internal controls for mRNAs and miR-375 were *GAPDH* and U6, respectively. The primers used are listed in [Table S2](#mmc1){ref-type="supplementary-material"}. The data were analyzed using the 2^−ΔΔCt^ relative expression method.

Immunofluorescence Staining {#sec4.8}
---------------------------

Lentivirus-infected hASCs were seeded in 24-well plates. After 14 days of osteoinduction, cells grown on sterile glass coverslips were fixed in 4% paraformaldehyde for 30 min, permeabilized with 0.1% Triton X-100 for 15 min, and blocked with 5% normal goat serum for 30 min. Thereafter, cells were incubated with a primary antibody (1:200) against osteocalcin (OCN; Abcam) overnight at 4°C, then incubated in the presence of an anti-mouse secondary antibody (1:500; Cell Signaling Technology) for 1 hr at room temperature. Nuclei were counterstained with 4′,6-diamidino-2-phenylindole (DAPI), and the coverslips were mounted on a glass slides and viewed under a Confocal Zeiss Axiovert 650 microscope at wavelengths of 488 nm (green, OCN) and 405 nm (blue, DAPI). Images were captured using an LSM 5 Exciter confocal imaging system (Carl Zeiss).

Western Blot Analysis {#sec4.9}
---------------------

After 7 and 14 days of osteoinduction, infected hASCs were harvested, washed with PBS, and lysed in RIPA buffer containing 1% PMSF (Sigma-Aldrich). For mechanistic evaluation of miR-375, total proteins were extracted after 7 days of osteoinduction. For evaluation of osteogenesis, total proteins were extracted after 14 days of osteoinduction. Primary antibodies against RUNX2, DEPTOR, p-S6K (Thr389), p-mTOR (Ser2448), mTOR, p-AKT (Ser473), AKT, p-IRS1 (Ser636/639), and YAP1 (Cell Signaling Technology), and OCN and GAPDH (Abcam) were diluted 1:1,000 and incubated with the membranes at 4°C overnight. Horseradish peroxidase-conjugated anti-rabbit or anti-mouse secondary antibodies (Cell Signaling) were diluted 1:10,000 and incubated with the membranes at room temperature for 1 hr. The membranes were then visualized using an ECL kit (CWBIO). Band intensities were quantified using ImageJ software (<https://imagej.nih.gov/ij/>). The background was subtracted, and the signal of each target band was normalized to that of the GAPDH band.

Reporter Vector Construction {#sec4.10}
----------------------------

Reporter vectors were constructed by Integrated Biotech Solutions. In brief, the 3′ UTRs of *DEPTOR* and *YAP1* containing the predicted miR-375 binding sites were synthesized and cloned into a modified version of pcDNA3.1(+) that contained a firefly luciferase reporter gene (a gift from Professor Brigid L.M. Hogan, Duke University), at a position downstream of the luciferase reporter gene. Site-directed mutagenesis of selected putative seeding-sequence regions was performed using a Site-Directed Mutagenesis Kit (SBS Genetech). All constructs were confirmed by DNA sequencing.

Promoter Construction {#sec4.11}
---------------------

Putative promoter of human miR-375 was amplified from the genomic DNA of HeLa cells and cloned into the PGL3-Enhancer vector (Promega). The primers for cloning the wild-type miR-375 promoter were as follows: sense, 5′-GGT GCC GTA CTT CCG CCA ATT-3′ and anti-sense, 5′-TCG CCC TCG GTG ATC TCC TG-3′. Site-directed mutagenesis of YAP1-TEAD binding site on the miR-375 promoter was performed using a Site-Directed Mutagenesis Kit (SBS Genetech). The luciferase reporter plasmids containing the wild-type miR-375 promoter and the mutation of YAP1 binding site (−1,692/−1,687 bp) on the miR-375 promoter were constructed as above. All constructs were confirmed by DNA sequencing.

Dual-Luciferase Reporter Assay {#sec4.12}
------------------------------

Luciferase reporter assays were performed as described previously ([@bib21]). In brief, 293T cells were grown in a 48-well plate and co-transfected with 400 ng of either control plasmid or plasmid-expressing targeting gene, 40 ng of the firefly luciferase reporter plasmid, and 4 ng of pRL-TK, a plasmid-expressing Renilla luciferase (Promega). Renilla and firefly luciferase activities were measured 24 hr after transfection using the Dual-Luciferase Reporter Assay System (Promega). All luciferase values were normalized to those of Renilla luciferase and expressed as fold induction relative to the basal activity.

Chromatin Immunoprecipitation Assay {#sec4.13}
-----------------------------------

ChIP assays were performed using an EZ-Magna ChIP assay kit (Merck Millipore) according to the manufacturer\'s instructions. hASCs were seeded in 10-cm dishes and transfected with *YAP1* siRNA or the NC. After 48 hr, cells were crosslinked with 1% formaldehyde, collected, lysed, and sonicated to shear DNA. Then the DNA-protein complexes were isolated with antibodies against isotype immunoglobulin G (IgG) and YAP1 (Cell Signaling). The protein-DNA complexes were then eluted and reverse-crosslinked. Spin columns were used to purify the DNA, which was quantified by qRT-PCR. Relative enrichment was calculated as the amount of amplified DNA normalized to the input and relative to values obtained from immunoprecipitation using normal IgG. The primers used are listed in [Table S2](#mmc1){ref-type="supplementary-material"}.

Microarray and Bioinformatics {#sec4.14}
-----------------------------

After 7 days of osteoinduction, total RNA was isolated from hASCs transfected with miR-375 and NC. Biotinylated cDNA was prepared according to the standard Affymetrix protocol from 250 ng of total RNA by using the Ambion WT Expression Kit (Thermo Fisher Scientific). Following labeling, 5.5 μg of cDNA was hybridized for 16 hr at 45°C on a GeneChip Human Transcriptome Array 2.0. GeneChips were washed and stained in the Affymetrix Fluidics Station 450. GeneChips were scanned by using the Affymetrix GeneChip Command Console (GPL15207, CapitalBio) installed in a GeneChip Scanner 3000 7G. Data were analyzed using the robust multichip analysis (RMA) algorithm with the Affymetrix default analysis settings. Values presented are log~2~ RMA signal intensities. For the calling of differentially expressed genes, the fold differences (≥1.5 and ≤0.667), false discovery rate (\<0.001), and average expression were used. For the gene ontology enrichment and KEGG pathway analysis, the DAVID webserver (<http://david.ncifcrf.gov/>) was used.

In Vivo Implantation of hASCs and SynthoGraft Hybrids {#sec4.15}
-----------------------------------------------------

hASCs at the fourth passage infected with lentivirus (miR-375 or NC) were cultured in OM for 7 days prior to the in vivo study. After being trypsinized and resuspended directly in DMEM, the cells were incubated with synthograft (β-tricalcium phosphate; Bicon) for 1 hr at 37°C, followed by centrifugation at 150 × *g* for 5 min, then implanted into two symmetrical sites on the dorsal subcutaneous space of 6-week-old BALB/c homozygous nude (nu/nu) mice (n = 6 per group). This study was approved by the Institutional Animal Care and Use Committee of the Peking University Health Science Center (LA2014233), and all animal experiments were performed in accordance with the Institutional Animal Guidelines.

Analyses of Bone Formation In Vivo {#sec4.16}
----------------------------------

Specimens were harvested 8 weeks after implantation, and the animals were euthanized by CO~2~ asphyxiation. After fixation in 4% paraformaldehyde, the specimens were analyzed by high-resolution Inveon micro-CT (Siemens). In brief, an X-ray voltage of 80 kV, a node current of 500 μA, and an exposure time of 500 ms for each of the 360 rotational steps were used. For quantitative analysis of the images, the BV/TV) and BS/TV ratios were calculated using the Inveon Research Workplace software. The specimens were then decalcified in 10% EDTA (pH 7.4) for 14 days, followed by dehydration and embedding with paraffin. Sections (5 μm thickness) were cut and stained with H&E and Masson\'s trichrome. Immunohistochemical staining was performed with a primary antibody against OCN (Abcam) to investigate osteogenesis. Tissue slices were visualized under a light microscope (Olympus).

Statistical Analysis {#sec4.17}
--------------------

Statistical analysis was performed using the SPSS Statistics 20.0 software (IBM). Data are expressed as mean ± SD of three independent experiments. Differences between two groups were analyzed by a Student\'s t test. For the testing of multiple groups, a one-way ANOVA was conducted. A two-tailed p value of \<0.05 was considered to indicate statistical significance.
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![miR-375 Is Upregulated during the Osteogenic Differentiation of hASCs\
(A) Relative expression of miR-375 at various time points during the osteogenic differentiation of hASCs as determined by qRT-PCR. U6 was used for normalization.\
(B--D) Relative mRNA levels of the osteogenic markers *RUNX2*, *ALP*, and *OCN* at various time points during the osteogenic differentiation of hASCs as determined by qRT-PCR. *GAPDH* was used for normalization.\
Data are presented as mean ± SD. ^∗^p \< 0.05, ^∗∗^p \< 0.01 (n = 3 independent experiments).](gr1){#fig1}

![miR-375 Overexpression Promotes the Osteogenic Differentiation of hASCs\
hASCs were transfected with lentivirus expressing miR-375 or control vector (NC), and cultured in proliferation medium (PM) or osteogenic medium (OM).\
(A) Alkaline phosphatase (ALP) staining on day 7, alizarin red S (ARS) staining on day 14, and von Kossa (VK) staining on day 21 after osteogenic induction.\
(B) ALP activity on day 7 and ARS mineralization assay on day 14 after osteogenic induction.\
(C) Relative mRNA levels of *RUNX2* and *ALP* measured by qRT-PCR on day 7 of osteogenic induction. Relative mRNA levels of *OSX* and *OCN* measured by qRT-PCR on day 14 of osteogenic induction. *GAPDH* was used for normalization.\
(D) Confocal microscopy of OCN with DAPI counterstaining on day 14 after osteogenic induction. Scale bars, 200 μm.\
(E) Left: western blot of OCN protein level on day 14 after osteogenic induction. GAPDH was used as the internal control. Right: quantification of band intensities.\
Data are presented as mean ± SD. ^∗^p \< 0.05, ^∗∗^p \< 0.01 (n = 3 independent experiments). See also [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.](gr2){#fig2}

![miR-375 Overexpression Promotes Heterotopic Bone Formation In Vivo\
(A) Schematic of the experimental setup.\
(B) H&E staining, Masson\'s trichrome staining, and immunohistochemical staining of OCN in miR-375 and NC groups. Scale bars, 50 μm.\
See also [Figure S3](#mmc1){ref-type="supplementary-material"}.](gr3){#fig3}

![miR-375 Overexpression Inhibits *DEPTOR* by Targeting Its 3′ UTR\
hASCs were transfected with lentivirus expressing miR-375 or control vector (NC).\
(A) 106 genes (red block) were upregulated and 91 (green block) were downregulated in miR-375-overexpressing hASCs 7 days after osteoinduction. A change ≥1.5 indicates upregulation and ≤0.667 indicates downregulation.\
(B) Enriched pathway analysis with miR-375 overexpression in hASCs 7 days after osteogenic induction.\
(C) Relative mRNA expression of *DEPTOR* measured by qRT-PCR in miR-375 and NC groups. *GAPDH* was used for normalization.\
(D) Left: western blot of DEPTOR protein levels in miR-375 and NC groups. GAPDH was used as the internal control. Right: quantification of band intensities.\
(E) Predicted binding site of miR-375 in the 3′ UTR of *DEPTOR*-WT mRNA (mutated bases in the 3′ UTR of *DEPTOR*-MT are underlined).\
(F) Luciferase activity of cells with miR-375 overexpression in *DEPTOR*-WT and *DEPTOR*-MT groups.\
Data are presented as mean ± SD. ^∗∗^p \< 0.01 (n = 3 independent experiments). See also [Table S1](#mmc1){ref-type="supplementary-material"}.](gr4){#fig4}

![*DEPTOR* Knockdown Promotes the Osteogenic Differentiation of hASCs\
(A) Relative expression of *DEPTOR* at various time points during the osteogenic differentiation of hASCs as determined by qRT-PCR. *GAPDH* was used for normalization.\
(B) *DEPTOR* expression is negatively correlated with that of miR-375 during the osteogenic differentiation of hASCs. *DEPTOR* and miR-375 expression was determined by qRT-PCR; *DEPTOR* expression was normalized to that of *GAPDH*, whereas miR-375 was normalized to U6. p and R values were calculated using Spearman\'s correlation tests.\
(C) Relative mRNA levels of *DEPTOR* at 48 hr after transfection of hASCs with *DEPTOR* siRNA (si-*DEP*1, si-*DEP*2) or the control vector (si-*NC*). *GAPDH* was used for normalization.\
(D) Western blot of DEPTOR protein levels 48 hr after transfection of hASCs with *DEPTOR* siRNA or control vector. GAPDH was used as the internal control.\
(E--H) hASCs were transfected with *DEPTOR* siRNA or control vector and cultured in PM or OM. (E) Alkaline phosphatase (ALP) staining on day 7 and alizarin red S (ARS) staining on day 14 after osteogenic induction. (F) ALP activity on day 7 and ARS mineralization assay on day 14 after osteogenic induction. (G) Relative mRNA levels of *RUNX2* and *OCN* measured by qRT-PCR on day 14 after osteogenic induction. *GAPDH* was used for normalization. (H) Left: western blot of RUNX2 and OCN protein levels on day 14 after osteogenic induction. GAPDH was used as the internal control. Right: quantification of band intensities.\
Data are presented as mean ± SD. ^∗^p \< 0.05, ^∗∗^p \< 0.01 (n = 3 independent experiments).](gr5){#fig5}

![miR-375 Inhibits AKT Signaling by Directly Targeting *DEPTOR*\
(A and B) Knockdown of *DEPTOR* inhibited AKT signaling through feedback inhibition of S6K-IRS1-AKT pathway in hASCs, which was evidenced by upregulation of p-S6K (Thr389), downregulation of p-mTOR (Ser2448), inhibition of p-AKT (Ser473), and p-IRS1 (Ser636/639). GAPDH was used as the internal control. Bar graphs (B) show the quantification of band intensities.\
(C and D) Expression analysis of AKT signaling with miR-375 overexpression in hASCs. Protein levels of p-S6K (Thr389), p-mTOR (Ser2448), t-mTOR, p-AKT (Ser473), t-AKT, and p-IRS1 (Ser636/639) were determined by western bolt analysis. GAPDH was used as the internal control. Bar graphs (D) show the quantification of band intensities.\
Data are presented as mean ± SD. ^∗^p \< 0.05, ^∗∗^p \< 0.01 (n = 3 independent experiments).](gr6){#fig6}

![YAP1 Negatively Regulates miR-375 by Binding to Its Promoter\
hASCs were transfected with *YAP1* siRNA (si-*YAP1*-1, si-*YAP1*-2) or the control vector (si-NC).\
(A) Western blot of YAP1 protein levels in the si-*YAP1*-1, si-*YAP1*-2, and si-*NC* groups. GAPDH was used as the internal control.\
(B) Relative expression of miR-375 in the si-*YAP1*-1, si-*YAP1*-2, and si-*NC* groups as determined by qRT-PCR. U6 was used for normalization.\
(C) Diagram of the miR-375 promoter and location of the primers. The positions marked are relative to the transcription start site (TSS).\
(D) ChIP-qPCR showing the interaction between the YAP1 and the miR-375 promoter in hASCs in the si-*YAP1*-1 and si-*NC* groups. IgG was used for normalization.\
(E) The YAP1 binding site on the miR-375 promoter (bottom) and mutation of YAP1 binding site (top).\
(F) Knockdown of *YAP1* increased the luciferase reporter activity of the wild-type, but not the mutant miR-375 promoter.\
Data are presented as mean ± SD. ^∗∗^p \< 0.01 (n = 3 independent experiments). See also [Figures S4](#mmc1){ref-type="supplementary-material"} and [S5](#mmc1){ref-type="supplementary-material"}.](gr7){#fig7}
